Page 16 - பார்மா சின்த் சூத்திரங்கள் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பார்மா சின்த் சூத்திரங்கள் வரையறுக்கப்பட்டவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பார்மா சின்த் சூத்திரங்கள் வரையறுக்கப்பட்டவை Today - Breaking & Trending Today

Can Bharat Biotech Deliver the Covaxin Doses It Promised?


Comments
As per Government of India projections, Bharat Biotech will deliver 55 crore doses of its COVID-19 Covaxin between August to December.
But as we crunch numbers, and look at these projections - it s clear that those goals are highly inflated.
While the government has roped in some pharma Public Sector Undertakings (PSUs) to expand Covaxin s production, those timelines extend well beyond 2021.
But before we get into any more details, it s important to underline that Bharat Biotech has till date not released full phase 3 data of its vaccine, months after concluding the trials, and months since the vaccine has already been administered to millions of people. ....

Serum Institute Covishield , Supreme Court , Bharat Biotech , Vaccine Targets , Indian Immunologicals , Vaccinating India , உச்ச நீதிமன்றம் , பாரத் பயோடெக் , தடுப்பூசி இலக்குகள் ,

Bristol Myers sued over delayed approval of cancer cell therapy


Dive Brief:
A bank representing former Celgene shareholders has sued Bristol Myers Squibb, claiming the pharmaceutical company failed to work diligently to win U.S. approval of a cancer cell therapy it acquired in its 2019 takeover of Celgene.
The therapy, then known as liso-cel, was one of three drugs covered in an agreement between Bristol Myers and Celgene, which required Bristol Myers to pay an additional $6.4 billion to Celgene shareholders should all three receive Food and Drug Administration approval by certain dates. 
But the Dec. 31, 2020 deadline for liso-cel to win an OK passed without a decision from the FDA, which had found problems at two manufacturing sites Bristol Myers planned to use to make the therapy. The agreement, called a contingent value right, was therefore terminated, allowing Bristol Myers to avoid payment.  ....

Novarti Kymriah , Bristol Myer , Bristol Myers , Equiniti Trust Company On Dec , Drug Administration , Bristol Myers Squibb , Dive Brief , Equiniti Trust Company , Juno Therapeutics , பிரிஸ்டல் மையர் , பிரிஸ்டல் மைஸ் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , டைவ் சுருக்கமான , ஜூனோ சிகிச்சை ,